九洲药业 (603456.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

15.4x

EV/EBITDA

8.9x

Market Cap

CNY 13.85B

MomentumView details →

1D Return

−5.36%

YTD Return

−15.81%

RSI (14)

44.1

ValuationView details →

P/E (Fwd)

15.4x

EV/EBITDA

8.9x

Market Cap

CNY 13.85B

RSI (14)

44.1

MomentumView details →

1D Return

−5.36%

YTD Return

−15.81%

ProfitabilityView details →

Gross Margin

36.58%

Net Margin

12.49%

EBITDA Margin

25.73%

ROE (TTM)

7.33%

ROA (TTM)

6.16%

Asset Turnover

0.49x

GrowthView details →

Revenue YoY

+0.85%

EPS YoY

+5.46%

FCF YoY

+78.99%

Revenue CAGR 3Y

+0.39%

EPS CAGR 3Y

−9.60%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.24

EPS Surprise

−17.25%

Beats (12Q)

0/12

Next Q EPS Est

CNY 0.28

Avg Surprise (4Q)

−17.25%

Rev Surprise

−0.67%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

3.83x

Quick Ratio

2.79x

Div Yield

1.99%

Div Rate

CNY 0.30

Div Growth 1Y

−80.00%

Financials snapshotView financials →

Revenue (TTM)

5.22B

Net Income (TTM)

651.95M

Op. CF (TTM)

1.67B

Next earningsOct 23, 2026 →

Latest newsMore news →

Jiuzhou Pharmaceutical's wholly-owned subsidiary Jiuzhou Biomedicine (Taizhou) received drug registration certificates from China's National Medical Products Administration for its buspirone citrate tablets in 5mg and 10mg strengths.2d ago

Jiuzhou Pharmaceutical disclosed that its CDMO business new orders grew steadily in H1 2026, adding 66 early-stage clinical projects, 5 Phase III-to-pre-launch projects, and 5 commercial projects.19d ago

Similar companies

海正药业600267.SH 华润江中600750.SH 健友股份603707.SH Elanco Animal Health IncorporatedELAN Fujian Haixi Pharmaceuticals Co., Ltd.02637.HK Neurocrine Biosciences, Inc.NBIX Find similar companies →

Latest newsMore news →

Jiuzhou Pharmaceutical's wholly-owned subsidiary Jiuzhou Biomedicine (Taizhou) received drug registration certificates from China's National Medical Products Administration for its buspirone citrate tablets in 5mg and 10mg strengths.2d ago Jiuzhou Pharmaceutical disclosed that its CDMO business new orders grew steadily in H1 2026, adding 66 early-stage clinical projects, 5 Phase III-to-pre-launch projects, and 5 commercial projects.19d ago